News

Mexico City, Mexico – May 06, 2025 – Apotex Inc. (referred to as "Apotex" or "the Company") today announced it has entered into an exclusive licensing agreement with Formosa Pharmaceuticals ("Formosa", 6838.TW), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery, upon regulatory approval.

This acquisition introduces Apotex into the strategically attractive and growing Canadian health and wellness sector, leveraging our existing channel presence in pharmacies and expanding our channels to include health food stores, new professional channels including naturopathic doctors, and grocery retail channels. CanPrev, through its CanPrev, Cyto-Matrix, and Orange Naturals brands, has a broad range of more than 445 products sold in more than 3,400 retail locations across Canada and online. CanPrev will continue to serve consumers through its existing brands and distribution channels.

Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced an agreement with Formosa Pharmaceuticals ("Formosa") under which Apotex has the exclusive rights to market and distribute APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) in Canada upon approval. The agreement further expands Apotex's ophthalmic franchise, building off a licensing agreement with Harrow Inc. for five branded pharmaceutical products completed in February 2024.

Toripalimab becomes Apotex's first novel brand biologic medicine.

Acquisition marks a significant step in Apotex's growth strategy, advancing its position as a preferred Health Partner of Choice in the Americas.

Canada's largest pharmaceutical company, Apotex Inc. ("Apotex") and Searchlight Pharma Inc. ("Searchlight"), one of Canada's fastest growing companies, announced today that they have reached an agreement whereby Apotex will acquire Searchlight.

Harrow, Inc., a leading U.S. eyecare pharmaceutical company, and Apotex Inc., Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.

Investment from SK Capital to support Apotex’s next phase of growth and continued innovation for patient affordability

Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-Apixaban^™ tablets, Canada's first generic alternative to Eliquis^®

Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the Canadian launch of APO-Teriflunomide^™ tablets, a generic version of Aubagio^®, for the treatment of relapsing remitting multiple sclerosis (RRMS).

Apotex Corp. announced today its release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane® in the United States.